{"nctId":"NCT00346333","briefTitle":"Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A","startDateStruct":{"date":"2003-07"},"conditions":["Retinitis Pigmentosa"],"count":240,"armGroups":[{"label":"Lutein plus 15,000 IU/d Vitamin A","type":"EXPERIMENTAL","interventionNames":["Drug: Lutein"]},{"label":"Control plus 15,000 IU/d Vitamin A","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Cornstarch control"]}],"interventions":[{"name":"Lutein","otherNames":[]},{"name":"Cornstarch control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nOcular Criteria\n\n* RP, typical forms(i.e. elevated final dark adaptation threshold,retinal arteriolar narrowing,and reduced and delayed full-field ERGs).\n* Best-corrected visual acuity 20/100 or better\n* HFA program 30-2 total point score \\>= 250 decibels(dB)to a size V white test light\n* No confounding ocular disease such as glaucoma,uveitis,diabetic retinopathy,posterior subcapsular cataract more than 11% of total lens area (ie equivalent to P3 on Lens Opacity Classification System III)and pupil diameter after dilation less than 6 mm.\n\nDietary Criteria\n\n* Fruit and vegetable intake \\< 10 servings/d\n* Spinach or kale intake \\< 1 serving/d, i.e. \\<1/2 cup of cooked spinach or kale per day\n* Dietary lutein intake \\<=5.4 mg/d as estimated from food frequency questionnaire\n* No intake of cod liver oil or omega-3 capsules\n* Dietary preformed vitamin A intake \\<= 10,000 IU/d\n* Supplement intake \\<= 5,000 IU/d of Vitamin A and \\<= 30 IU/d of Vitamin E\n* Consumption \\<= 3 alcoholic beverages/d\n\nMedical and other criteria\n\n* Age 18-60 y\n* Body mass index \\< 40 and weight \\>= 5th percentile for age,gender,and height\n* Serum retinol level \\<= 100 micrograms/deciliter and serum retinyl ester level \\<= 380 nanomoles/Liter\n* Serum cholesterol \\< 300 micrograms/deciliter and serum triglyceride level \\<400 micrograms/deciliter\n* No clinically significant abnormality on blood cell count, glucose level, blood urea nitrogen level, serum lipid panel results or serum liver function profile.\n* Not pregnant or planning to become pregnant\n* Not smoking currently\n* Agreed not to know tablet content or course of condition until the end of the trial.\n* No other disease which might affect absorption or metabolism of lutein or vitamin A.\n* Only one patient per family was accepted into the study.\n\nExclusion Criteria:\n\n* Women who are pregnant or planning to become pregnant (Vitamin A supplements can increase the risk of birth defects.)\n* Current participation in another clinical trial for RP\n* Patients with atypical forms such as paravenous RP, pericentral RP, sector RP,unilateral RP,Refsum disease, Bardet-Biedl syndrome, retinitis punctata albescens and cone-rod dystrophy were excluded as were patients with RP and profound congenital deafness.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Central Visual Field (vf) Change Assessed Using the 30-2 Program of the Humphrey Field Analyzer (HFA).","description":"Sum of visual field sensitivity readings in decibel(dB) to a size V target out to the 30 degree meridian in each direction of the visual field. The value presented represents annual change in dB over 4 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.5","spread":"3.2"},{"groupId":"OG001","value":"-49.6","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Mid-peripheral Field Change Assessed With the 60-4 Program of the Humphrey Field Analyzer.","description":"Sum of visual field sensitivity readings in dB to a size V target from the 30 degree meridian to the 60 degree meridian in each direction of the visual field. The value presented represents annual change in dB over 4 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.1","spread":"3.0"},{"groupId":"OG001","value":"-26.6","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Total Field Change Assessed by the Combined 30-2 and 60-4 Programs of the Humphrey Field Analyzer.","description":"Sum of visual field sensitivity readings in dB to a size V target obtained with the 30-2 and 60-4 programs of the Humphrey Field Analyzer combined for those patients on whom both measures were available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.1","spread":"6.2"},{"groupId":"OG001","value":"-92.9","spread":"5.7"}]}]}]},{"type":"SECONDARY","title":"Annual Change in 30 Hertz(Hz)Electroretinogram(ERG )Amplitude in Natural Log (ln) Microvolts/yr Over a 4 Year Period.","description":"Computer averaged 30 Hz ERG amplitudes in microvolts for those with initial amplitudes of \\>= 0.68 microvolts. Presented on the ln scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.12"},{"groupId":"OG001","value":"-0.09","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity","description":"Annual change in number of letters read.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.12"},{"groupId":"OG001","value":"-0.53","spread":"0.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":[]}}}